
Takeda is teaming up with Canadian biotech enGene to develop novel therapies for specialty gastrointestinal (GI) diseases, using enGene’s ‘gene …

AstraZeneca’s biologics R&D arm MedImmune and the University of California, San Francisco (UCSF) have announced a new research collaboration focused …

US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development …

Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …

The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …

Work has begun to transform a 20-acre site that formerly housed Novartis, in West Sussex, into a world renowned centre …

AstraZeneca and its biologics arm MedImmune are launching new agreements with partner companies, to develop new targets for cancer, and …

Drugs giant Pfizer raised the prices of more than 100 of its drugs in the US on 1 January, in …

Celgene president and chief operating officer Mike Alles has been promoted to the top job after an executive restructure at …

The recent reimbursement wrangle between PTC Therapeutics and NICE, the UK healthcare watchdog, has once again raised difficult questions about …

Roche has acquired Tensha Therapeutics, a privately-held company based in Cambridge, Massachusetts for up to $535 million.The deal that gives …

Genomics has appointed Dr Sekar Kathiresan as chair of the company’s newly-formed scientific advisory board as chair, with immediate effect. Dr …

AbbVie has announced it has begun six global Phase III trials of its once-daily, ribavirin-free investigational hepatitis C virus regimen, …

Neil Burrows has joined as head of global media relations, following Esra Erkal-Paler’s promotion to head of global external communications.Burrows …

One of the industry’s longest-running M&A sagas has finally reached a conclusion, with Shire and Baxalta announcing a $32 billion …

AbbVie has begun a large phase III clinical trial programme for its next-generation rheumatoid arthritis (RA) treatment ABT-494, which the …

Sanofi has signed two separate research agreements for €1.2 billion, which will give the French firm licensing rights to potential …

Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology, as it moves …

GSK has put into practice its pledge to halt payments to doctors to promote its products at medical seminars – …

Mylan has entered an exclusive global collaboration agreement with Momenta Pharmaceuticals, to develop, manufacture and commercialise six of Momenta’s biosimilar …